Phase One validated pains and positioning evidence

Raw source preview

Raw, unprocessed file text shown below.

---
title: "Phase One Validated Pains & Positioning Evidence Base"
status: active
last_updated: '2026-06-12'
purpose: Canonical starting point for all positioning, messaging, and hero-copy work. Separates what the Phase One research actually validated from what is EmpathyIQ thesis, and records the provenance rules that stop the two being conflated again.
tags: [market-analysis, positioning, evidence, phase-one, provenance, messaging]
---

# Phase One Validated Pains & Positioning Evidence Base

**Start here before writing any positioning, hero, or sales copy that makes a claim about what buyers feel, fear, or need.**

This document exists because a 2026-06-12 raw-source audit found that a brand thesis ("the buyer's fear is being asked to defend the research") had been laundered into a "validated market finding" across three layers of derived documents, and was about to anchor homepage hero copy. The audit corrected the affected documents (listed at the end) and produced this single evidence base so the mistake is structurally hard to repeat.

## How to use this document

Every buyer-pain claim used in positioning work carries one of three tags:

- **[VALIDATED]** — directly evidenced in the Phase One raw sources (debrief PDF and/or the IDI-derived persona docs). Safe to state as market fact, subject to the small-n caveat below.
- **[THESIS]** — EmpathyIQ's own point of view. May be argued in copy as our belief or as a product promise, but must never be cited as something "the research shows."
- **[INDUSTRY]** — supported by third-party industry sources (GRIT, Qualtrics trends, Mustard, etc.), not by our own interviews.

**Small-n caveat:** Phase One = 17 IDIs (March 2026). The quantitative challenge table = 6 Irish + 4 UK external raters. Personas are composites blending IDI transcripts with LinkedIn profiles and published sources. All findings are directional, not statistical.

## The validated pain map

| # | Pain | Tag | Evidence (raw source) | Markets |
|---|---|---|---|---|
| 1 | **Too slow for the business — but unwilling to cut corners.** Quality satisfaction is already high; the frustration is pace. | [VALIDATED] | Challenge table: "Improving speed, scale & agility" UK 9/10 (#1), IE 8/10 (joint #1). "Interviewees in both markets were broadly satisfied with research quality." Debrief on agencies: "They are slow. Agencies still operating on 6–8 week project timelines are being bypassed by clients who can get directional answers from AI tools in hours." | Both |
| 2 | **Insight doesn't travel — research dies after the debrief.** | [VALIDATED] | "Struggle to embed insight into the wider business was the single biggest theme in Irish interviews. This isn't about producing good research, it's about getting it to travel x functions & genuinely shape commercial strategy." Challenge table: "Embedding insight into business" IE 8/10, UK 7/10. "The insight industry has a delivery problem, not a methodology problem." Aoife's stated single biggest unmet need: help "making insight land, stick, and change behaviour within her organisation." One interviewee: the "insight experience" — "immersion in the data… going beyond the debrief… bring results to life in an immersive way." | Both, strongest IE |
| 3 | **Being bypassed — the relevance threat.** | [VALIDATED] | Debrief: slow agencies "are being bypassed by clients who can get directional answers from AI tools in hours." Charlotte: AI "makes it easier for non-researchers to bypass her function entirely. She is watching low-cost AI-powered platforms like Tracksuit and Zappi compress the market… she worries about what this means for her budget and her team's relevance." Persona: the challenge has evolved from "get insight to the table" to "make sure insight still matters when everyone has data." | Both; sharpest UK |
| 4 | **Budget / value defence — prove the function's worth.** Note carefully: the object of defence is the **spend and the function**, not the findings. | [VALIDATED — UK-weighted] | Debrief: "Cost focus isn't just about price. Evidence that insight functions are under pressure to prove value creation." UK "triple squeeze: less time, less budget & more challenges around activation & stakeholder management." Charlotte: "Defending her budget in a quarterly review where finance is asking why the brand tracker costs £200k when Tracksuit offers something for a fraction of the price." And: "I need to prove that every pound spent on insight is driving a commercial outcome. My board doesn't care how the research was done — they care what changed because of it." | UK (not raised in Irish IDIs) |
| 5 | **Ungoverned spread has already burned them.** Democratisation without governance produced fatigue, not influence. This is the constraint on pain #2 — travel must be governed travel. | [VALIDATED] | UK interviewee: "democratising insight through dashboards meant losing strategic depth." UK Participant 5: "The danger is that everyone deploys dashboards and self-serve analytics and thinks they've solved the insight problem. They haven't. They've just created dashboard fatigue." Aoife: wants to democratise insight "but worries about quality and misinterpretation." | Both |
| 6 | **AI: pressure without an operating model.** Everyone experiments; nobody has a strategy; the window to be the guide is open now. | [VALIDATED + INDUSTRY] | Irish Participant 1: "We're experimenting. People are using ChatGPT for bits and pieces — coding open-ends, tidying up transcripts. But nobody has a strategy for it yet." Debrief: "near-total absence of purpose-built research AI platforms" across both markets; both at Stage 1–2. [INDUSTRY] GRIT: brand-side satisfaction with AI tools 13%; general-purpose AI adoption falling while purpose-built grows. | Both |
| 7 | **Foresight and innovation appetite.** | [VALIDATED — no product coverage] | Challenge table: "Foresight, futures strategy & scenario planning" 8/8; "Innovation pipeline & horizon scanning" 8/8 — top-tier in both markets. **Do not use in hero or near-term copy: EIQ ships nothing here today (6 months+ roadmap).** | Both |

## The thesis register

Things we believe and build for, which Phase One did **not** validate. These may appear in copy as our point of view or product promise — never as recorded buyer pain.

| Thesis | Tag | Actual support | What would validate it |
|---|---|---|---|
| **Finding-level defensibility:** stakeholders challenge individual findings ("how do we know this is right?") and the team must produce supporting evidence on the spot. | [THESIS] | EmpathyIQ's own positioning history (pre-Phase-One confidence docs); plausibility; adjacency to validated pains 3–4. Charlotte's quote cuts the other way: "My board doesn't care how the research was done — they care what changed because of it." | Pilot-customer feedback (Musgrave, UKOmnibus), buyer reactions to Research Guard / Trust Centre demos, win-loss notes. |
| **Data-quality anxiety as buying trigger** (fraud, synthetic respondents, bad sample). | [INDUSTRY] | Debrief appendix citing industry data: "data quality remains the top industry concern, with worries increasing 40% YoY driven by synthetic respondents." Not raised by our own interviewees as a personal pain. | Same as above; also field evidence from pilots. |
| **"How do we know this is right?"** as a buyer phrase. | [THESIS — our copy] | This is EmpathyIQ marketing language. It appears in no interview. Never cite it as evidence; it may still be used *as copy* if it tests well with real buyers. | Buyer language testing. |

## What this means for positioning (standing direction, 2026-06-12)

1. The two pains positioning must lead with are **speed-without-corners** (#1) and **governed travel** (#2 constrained by #5). The emotional unifier underneath both is **bypass/relevance** (#3).
2. The differentiator vs Qualtrics / Gyde-FuelCycle / Stravito is the **combination** — rigorous production *and* governed spread under one evidence chain — not any single claim, all of which are individually contested (see founder synthesis §3).
3. Sequencing rule from the founder synthesis still holds: production credibility opens the conversation; activation is the climax, not the opener.
4. Finding-level defensibility moves from "validated fear" to **brand thesis**: it remains a real product capability story (Research Guard, Trust Centre, claim-to-source), told as our point of view and proven in demos — not asserted as what buyers said they fear.
5. Hero status: beats 1 (speed) and 3 (travel) are evidence-fixed; beat 2 is an open decision — see `website/06-decision-register.md` D-003 round 3.

## Provenance rules (the "never again" list)

1. **Raw sources only for market-pain claims.** Any claim about what buyers feel/fear/need that reaches external copy must trace to the debrief PDF or persona docs (or a named pilot conversation) — not to a derived synthesis, however senior. Derived memos are interpretation layers, and this audit showed they drift.
2. **Our copy is never evidence.** EmpathyIQ marketing lines must never appear in an "evidence" or "anchor" column. If a phrase originated with us, tag it [THESIS — our copy].
3. **Tag every pain claim** [VALIDATED] / [THESIS] / [INDUSTRY] in positioning and GTM docs. Untagged claims should be treated as unverified.
4. **Name the market.** UK-only evidence (budget defence, triple squeeze, procurement proof) must not be generalised to "both markets."
5. **Check the object of the verb.** "Defend the budget" ≠ "defend the findings." "Agencies get bypassed" ≠ "insight teams get bypassed" (both happen to be evidenced, but each was verified separately).
6. **Keep the n honest.** 17 IDIs, 10 quant raters, composite personas — directional language only ("interviewees described", not "the market demands").

## Audit record (2026-06-12)

The drift: EmpathyIQ's pre-Phase-One confidence thesis → `unknown-phase-one-synthesis-2026-04-20.md` mapped debrief findings onto it and stamped "✅ Confirmed" → founder synthesis inherited it as "'how do we know this is right?' framing appears across both markets" → nearly anchored hero copy. Corrections applied to:

- `market-analysis/source-material/phase-one-debrief/unknown-phase-one-synthesis-2026-04-20.md` (origin row corrected + provenance note)
- `market-analysis/source-material/phase-one-debrief/eiq-phase-one-founder-synthesis-2026-04-22.md` (exec summary, Angle A row 2, Angle B stage 2 + provenance note)
- `market-analysis/source-material/phase-one-debrief/eiq-phase-one-implications-memo-codex-5-4-extra-effort-2026-04-21.md` (provenance caution banner; archived)
- `market-analysis/source-material/phase-one-debrief/eiq-phase-one-independent-review-claude-code-opus-4-7-max-2026-04-21.md` (provenance caution banner; archived)
- `market-analysis/source-material/phase-one-debrief/eiq-internal-external-business-unit-synthesis-2026-04-22.md` (banner + client-pain cell corrected)
- `market-analysis/audience-profiles.md` (shared-pressure bullet, "Credibility and trust" section, platform-wants list)
- `website/claim-support-register.md` (hero market-pain claims added as governed claims)
- `website/06-decision-register.md` (D-003 round 3)

## Source base

- **Raw:** `market-analysis/source-material/phase-one-debrief/Unknown Phase One Debrief 8 Apr 2026.pdf` (full-text extracted and searched 2026-06-12); `market-analysis/source-material/audience-profiles/Irish_Insight_Leader_Persona.docx`; `market-analysis/source-material/audience-profiles/UK_Insight_Leader_Persona.docx`
- **Derived (read with their correction notes):** founder synthesis 2026-04-22; implications memo 2026-04-21; independent review 2026-04-21; unknown-phase-one-synthesis 2026-04-20
- **Canon:** `market-analysis/audience-profiles.md`